Cargando…

Effects of Topical Bimatoprost 0.01% and Timolol 0.5% on Circadian IOP, Blood Pressure and Perfusion Pressure in Patients with Glaucoma or Ocular Hypertension: A Randomized, Double Masked, Placebo-Controlled Clinical Trial

PURPOSE: To compare the 24-hour (24h) effects on intraocular pressure (IOP) and cardiovascular parameters of timolol 0.5% and bimatoprost 0.01% in open angle glaucoma and ocular hypertensive subjects. METHODS: In this prospective, randomized, double masked, crossover, clinical trial, after washout f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oddone, Francesco, Rossetti, Luca, Tanga, Lucia, Berardo, Francesca, Ferrazza, Manuela, Michelessi, Manuele, Roberti, Gloria, Manni, Gianluca, Centofanti, Marco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4615626/ https://www.ncbi.nlm.nih.gov/pubmed/26484767 http://dx.doi.org/10.1371/journal.pone.0140601

Ejemplares similares

Efficacy and safety of fixed-combination travoprost 0.004%/timolol 0.5% in patients transitioning from bimatoprost 0.03%/timolol 0.5% combination therapy
por: Schnober, Dietmar, et al.
Publicado: (2015)

Managing refractory glaucoma with a fixed combination of bimatoprost (0.03%) and timolol (0.5%)
por: Gheith, Moataz E, et al.
Publicado: (2008)

Impact of topical bimatoprost 0.01% and bimatoprost 0.03% on conjunctival irritation in rabbits
por: Ogundele, Abayomi B, et al.
Publicado: (2010)

Aqueous humor penetration of topical bimatoprost 0.01% and bimatoprost 0.03% in rabbits
por: Ogundele, Abayomi B, et al.
Publicado: (2010)

Bimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or ocular hypertension: a 12-week randomised controlled trial
por: Goldberg, Ivan, et al.
Publicado: (2014)

Twenty-four-hour effects of bimatoprost 0.01% monotherapy on intraocular pressure and ocular perfusion pressure
por: Tung, Jonathan D, et al.
Publicado: (2012)

Preservative-free bimatoprost 0.03%/timolol 0.5% fixed combination in patients with glaucoma in clinical practice
por: Pfennigsdorf, Stefan, et al.
Publicado: (2016)

Evaluating the effect of pupil dilation on spectral-domain optical coherence tomography measurements and their quality score
por: Tanga, Lucia, et al.
Publicado: (2015)

Aqueous humor penetration of topical bimatoprost 0.01% and bimatoprost 0.03% in rabbits: response to authors
por: Chang-Lin, Joan-En, et al.
Publicado: (2011)

Evaluating intraocular pressure-lowering solutions for the treatment of open-angle glaucoma: comparison between bimatoprost 0.03% and bimatoprost 0.01% — an observational switch study
por: Deshpande, Sarita S, et al.
Publicado: (2017)

Retrospective Analysis of Switching Bimatoprost 0.01% to Bimatoprost 0.03% in Patients with Various Types of Glaucoma and Ocular Hypertension
por: Xu, Kai Man, et al.
Publicado: (2022)

Comparing the Efficacy of Latanoprost (0.005%), Bimatoprost (0.03%), Travoprost (0.004%), and Timolol (0.5%) in the Treatment of Primary Open Angle Glaucoma
por: Mishra, Deepak, et al.
Publicado: (2014)

Cytidine 5′-Diphosphocholine (Citicoline) in Glaucoma: Rationale of Its Use, Current Evidence and Future Perspectives
por: Roberti, Gloria, et al.
Publicado: (2015)

Fixed combination of topical brimonidine 0.2% and timolol 0.5% for glaucoma and uncontrolled intraocular pressure
por: Lee, Anne J, et al.
Publicado: (2008)

p < 0.05, < 0.01, < 0.001, < 0.0001, < 0.00001, < 0.000001, or < 0.0000001 …
por: Zhu, Weimo
Publicado: (2016)

Fixed combination of bimatoprost and timolol in patients with primary open-angle glaucoma or ocular hypertension with inadequate IOP adjustment
por: Brief, Gerrett, et al.
Publicado: (2010)

Pressure Dependence of Superconducting Properties, Pinning Mechanism, and Crystal Structure of the Fe(0.99)Mn(0.01)Se(0.5)Te(0.5) Superconductor
por: Murugesan, Kannan, et al.
Publicado: (2021)

Comparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on 24-hour blood and ocular perfusion pressures: the results of a randomized trial
por: Rossetti, Luca, et al.
Publicado: (2015)

Safety of Fixed-Combination Bimatoprost 0.03%/Timolol 0.5% Ophthalmic Solution at 6 Months in Chinese Patients with Open-Angle Glaucoma or Ocular Hypertension
por: Sun, Xinghuai, et al.
Publicado: (2022)

Diurnal Intraocular Pressure with Bimatoprost/Timolol Fixed Combination versus Latanoprost/Timolol Fixed Combination in Healthy Subjects
por: Shim, Seong Hee, et al.
Publicado: (2014)

Randomized Multicenter Clinical Trial Comparing 0.1% Brimonidine/0.5% Timolol Versus 1% Dorzolamide/0.5% Timolol as Adjuncts to Prostaglandin Analogues: Aibeta Crossover Study
por: Inatani, Masaru, et al.
Publicado: (2023)

Safety and efficacy of switching from dorzolamide 1.0%/timolol maleate 0.5% eye drops to brinzolamide 1.0%/timolol maleate 0.5% eye drops
por: Inoue, Kenji, et al.
Publicado: (2015)

Effect of 3 years of treatment with a dorzolamide/timolol (1%/0.5%) combination on intraocular pressure
por: Takeda, Sakurako, et al.
Publicado: (2014)

An observational study of bimatoprost 0.01% in patients on prior intraocular pressure-lowering therapy: the Canadian Lumigan(®) RC Early Analysis Review (CLEAR) trial
por: Crichton, Andrew C, et al.
Publicado: (2014)

Administration of the fixed combination of latanoprost 0.005% and timolol 0.5% in glaucoma patients with an intraocular pressure over 30 mmHg
por: Özkurt, Yelda Buyru, et al.
Publicado: (2009)

Late-day intraocular pressure–lowering efficacy and tolerability of travoprost 0.004% versus bimatoprost 0.01% in patients with open-angle glaucoma or ocular hypertension: a randomized trial
por: DuBiner, Harvey B, et al.
Publicado: (2014)

Comparison of the latanoprost 0.005%/timolol 0.5% + brinzolamide 1% versus dorzolamide 1%/timolol 0.5% + latanoprost 0.005%: a 12-week, randomized open-label trial
por: Nakakura, Shunsuke, et al.
Publicado: (2012)

Pooled results of two randomized clinical trials comparing the efficacy and safety of travoprost 0.004%/timolol 0.5% in fixed combination versus concomitant travoprost 0.004% and timolol 0.5%
por: Gross, Ronald L, et al.
Publicado: (2007)

Comparison of timolol 0.5% + brimonidine 0.2% + dorzolamide 2% versus timolol 0.5% + brimonidine 0.2% in a Mexican population with primary open-angle glaucoma or ocular hypertension
por: Baiza-Durán, Leopoldo Martín, et al.
Publicado: (2012)

Effect of preservative removal from fixed-combination bimatoprost/timolol on intraocular pressure lowering: a potential timolol dose–response phenomenon
por: Shen, Jie, et al.
Publicado: (2016)

Bimatoprost 0.01% or 0.03% in patients with glaucoma or ocular hypertension previously treated with latanoprost: two randomized 12-week trials
por: Myers, Jonathan S, et al.
Publicado: (2014)

Comparative study of the efficacy and safety of topical minoxidil 2% versus topical bimatoprost 0.01% versus topical bimatoprost 0.03% in treatment of eyebrow hypotrichosis: a randomized controlled trial
por: Zaky, Mohamed S., et al.
Publicado: (2023)

Additive effects and safety of fixed combination therapy with 1% brinzolamide and 0.5% timolol versus 1% dorzolamide and 0.5% timolol in prostaglandin‐treated glaucoma patients
por: Aihara, Makoto, et al.
Publicado: (2017)

A study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to latanoprost 0.005% and timolol 0.5% dosed concomitantly in patients with open-angle glaucoma or ocular hypertension
por: Rhee, Douglas J, et al.
Publicado: (2008)

Glaucoma Progression Diagnosis: The Agreement between Clinical Judgment and Statistical Software
por: Roberti, Gloria, et al.
Publicado: (2022)

Intraocular pressure reduction using a fixed combination of timolol maleate 0.5% and brimonidine tartrate 0.2% administered three times daily
por: Moisseiev, Elad, et al.
Publicado: (2013)

The effect of Timolol 0.5% on the correction of myopic regression after LASIK
por: Qi, Hong, et al.
Publicado: (2017)

Treatment persistence and cost-effectiveness of latanoprost/latanoprost–timolol, bimatoprost/bimatoprost–timolol, and travoprost/travoprost–timolol in glaucoma: an analysis based on the United Kingdom general practitioner research database
por: Lafuma, Antoine, et al.
Publicado: (2011)

A combined analysis of four observational studies evaluating the intraocular pressure-lowering ability and tolerability of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension
por: Stevens, Annemie, et al.
Publicado: (2016)

First-line treatment for elevated intraocular pressure (IOP) associated with open-angle glaucoma or ocular hypertension: focus on bimatoprost
por: Law, Simon K
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_5pko1mmg4g3pns5hup6085318o